Xeris Pharmaceuticals ( (XERS) ) has released its Q2 earnings. Here is a breakdown of the information Xeris Pharmaceuticals presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Xeris Biopharma Holdings, Inc., a biopharmaceutical company based in Chicago, focuses on developing and commercializing innovative therapies, including products like Recorlev, Gvoke, and Keveyis, with a robust pipeline of development programs.
In its latest earnings report, Xeris Biopharma announced record financial results for the second quarter of 2025, with a significant year-over-year revenue increase and an upward revision of its full-year revenue guidance. The company highlighted strong performance across its product portfolio, particularly with Recorlev.
Key financial metrics revealed a 49% increase in total revenue, reaching $71.5 million, driven by a 136% growth in Recorlev revenue. The company also reported an 87% improvement in net loss compared to the previous year, alongside a substantial increase in Adjusted EBITDA. Strategic updates included a long-term revenue outlook and growth strategy shared during its Analyst and Investor Day.
Looking ahead, Xeris Biopharma remains optimistic about its growth trajectory, raising its full-year revenue guidance and setting ambitious targets for 2030 and beyond. The company continues to focus on driving patient demand and executing its growth strategy across its portfolio.